CIK 0001649989
- Non-accelerated filer
- Smaller reporting company
Outlook Therapeutics, Inc.
Sign in to watch- Ticker
- OTLK
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 383982704
- Phone
- +1 609-619-3990
- Business address
- 111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
- Former names
- Oncobiologics, Inc.
- 4 Other acquisition Director acquired 18,518 shares (other)
- 4 Other acquisition Director acquired 57,408 shares (other)
- 4 Open-market sale Director sold 1 shares at $3.75 ($4)
- 4 Open-market sale SVP, Development & Mfrg sold 37,369 shares at $3.75 ($140,134)
- 4 Conversion Director acquired 144,927 shares (conversion)
- 4 Open-market sale SVP Bus. Strat. & Dev. sold 21,367 shares at $3.75 ($80,126)
- 4 Conversion Director acquired 57,971 shares (conversion)
- 4 Conversion Director acquired 28,985 shares (conversion)
- 4 Conversion President & CEO acquired 17,666 shares (conversion)
- 4 Conversion Director acquired 58,500 shares (conversion)
- 4 Conversion Director acquired 66,333 shares (conversion)
- 4 Open-market buy Chief Medical Officer bought 2,000 shares
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 15 of 16 · 305 filings